1. Home
  2. FURY vs ADVM Comparison

FURY vs ADVM Comparison

Compare FURY & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.60

Market Cap

97.7M

ML Signal

HOLD

Logo Adverum Biotechnologies Inc.

ADVM

Adverum Biotechnologies Inc.

HOLD

Current Price

$4.36

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
ADVM
Founded
2008
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
94.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
FURY
ADVM
Price
$0.60
$4.36
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$1.40
$11.60
AVG Volume (30 Days)
613.1K
497.5K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,192.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$1.78
52 Week High
$0.89
$6.12

Technical Indicators

Market Signals
Indicator
FURY
ADVM
Relative Strength Index (RSI) 51.05 58.20
Support Level $0.57 $4.15
Resistance Level $0.72 $4.23
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.02
Stochastic Oscillator 43.62 95.22

Price Performance

Historical Comparison
FURY
ADVM

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: